Canadian Diabetes Association

According to the Canadian Diabetes Association, four out of five people with diabetes die of heart disease. Other complications of diabetes include kidney and nerve damage, blindness, and sexual dysfunction. A study conducted by the University of Texas Southwestern Medical Center in Dallas found that people with Type 2 diabetes have highly acidic urine and are at greater risk of developing uric acid kidney stones.17... 

Acknowledgements. The work summarized here was supported by the Natural Sciences and Engineering Research Council, Medical Research Council, the Canadian Diabetes Association, the American Diabetes Association (WTKS), the Sedgewick Country mill levy fund (WTKS), the Ontario Centre for Materials Research (OCMR) and NIH (DK 29689). 

Given the limited evidence from clinical trials, the Canadian Diabetes Association issued low-level evidence ratings for the beneficial effects of PUFA, particularly LA, on diabetes (Canadian Diabetes Association, 2003). The current nutrition recommendations from the American Diabetes Association (ADA) do not include guidance about LA intake (American Diabetes Association, 2008). 

Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Clinical practice guidelines for the prevention and management of diabetes in Caruida. Can. J. Diabetes 2003 Suppl. 27, pp. S1-S152. 

Canadian Diabetes Association (CDA), Clinical practice guidelines expert committee.Dyslipidemia in adults with diabetes, Canadian J. Diabetes, 30 (2006) 230-240. 

Cheng, A.Y.Y., and Fantus, LG. 2005. Oral antihyperglycemic therapy for type 2 diabetes mel-litus. CMAJ Canadian Medical Association journal 172(2), 213-26. 

In a population-based Canadian cohort study [41] of 10,309 new users of metformin or sulfonylureas with an average follow-up of 5.4 years it was found that patients with type 2 diabetes exposed to sulfonylureas and exogenous insulin had a significantly increased risk of cancer-related mortality compared with patients exposed to metformin. Cancer mortality 4.9% (162 of 3,340) for sulfonylurea monotherapy users, 3.5% (245 of 6,969) for metformin users and 5.8% (84 of 1,443) for subjects who used insulin. After multivariate adjustment, the sulfonylurea cohort had greater cancer-related mortality compared with the metformin cohort (adjusted HR = 1.3 p = 0.012). Insulin use was associated with an adjusted HR of cancer-related mortality of 1.9 (p < 0.0001). It is unclear whether... 

---